Inspired by the “like cures like” principle on cancer treatment in Chinese Medicine, we utilized the bioactive anti-cancer molecule Bufalin as a probe, which was originally extracted from Venenum Bufonis, a typical toxic Chinese Medicine to screen out AHSA1 as the potential target in MM by proteome microarray and MM microarray cohorts. Here, AHSA1 is linked to Miyoshi myopathy.